Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2016-03-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-016-3359-8PMID 27003417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value?

  2015cited by this paper
• Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study

  2014cited by this paper
• Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

  2013influential reference
• Longitudinal Progression of Cognitive Decline Correlates with Changes in the Spatial Pattern of Brain 18F-FDG PET

  2013cited by this paper
• BrainNet Viewer: A Network Visualization Tool for Human Brain Connectomics

  2013cited by this paper
• Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [18F]AV-45 Positron Emission Tomography in Chinese Population

  2013cited by this paper
• Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease

  2012cited by this paper
• Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies

  2012cited by this paper
• Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer’s disease measured by pulsed arterial spin labeling MRI

  2012cited by this paper
• Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease

  2012cited by this paper
• Dissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive Impairment

  2012cited by this paper
• Amyloid deposition, hypometabolism, and longitudinal cognitive decline

  2012cited by this paper
• Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Use of florbetapir-PET for imaging beta-amyloid pathology.

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Use of Florbetapir-PET for Imaging-Amyloid Pathology

  2011cited by this paper
• Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

  2011cited by this paper
• Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B

  2011cited by this paper
• Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients

  2011cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.

  2010cited by this paper
• Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.

  2010cited by this paper
• Concordance and Discordance Between Brain Perfusion and Atrophy in Frontotemporal Dementia

  2010cited by this paper
• Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease

  2009cited by this paper
• Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

  2008cited by this paper
• Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study

  2008cited by this paper
• Regional Differences in the Coupling between Resting Cerebral Blood Flow and Metabolism may Indicate Action Preparedness as a Default State

  2008cited by this paper
• Evaluation of the Metabotropic Glutamate Receptor Subtype 5 Using PET and 11C-ABP688: Assessment of Methods

  2007cited by this paper
• Brain imaging evidence of preclinical Alzheimer's disease in normal aging

  2006cited by this paper
• Neuropathologic features of amnestic mild cognitive impairment.

  2006cited by this paper
• BMC Nuclear Medicine BioMed Central

  2006cited by this paper
• PET imaging in the assessment of normal and impaired cognitive function.

  2005cited by this paper
• 11C-DTBZ and 18F-FDG PET measures in differentiating dementias.

  2005cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

  2004cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)

  2003cited by this paper
• Segmented regression analysis of interrupted time series studies in medication use research

  2002cited by this paper
• Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

  2002cited by this paper
• Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load.

  2001cited by this paper
• Current concepts in mild cognitive impairment.

  2001cited by this paper
• Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.

  1998cited by this paper
• Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization.

  1998cited by this paper
• Diagnosis of Alzheimer's Disease in a Community Hospital-Based Brain Bank Program

  1997cited by this paper
• Prevalence of dementia in an urban area in taiwan.

  1996cited by this paper
• A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM).

  1995cited by this paper
• A Probabilistic Atlas of the Human Brain: Theory and Rationale for Its Development: The International Consortium for Brain Mapping (ICBM)

  1995cited by this paper
• Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI.

  1995cited by this paper
• Kinetic behavior of technetium-99m-HMPAO in the human brain and quantification of cerebral blood flow using dynamic SPECT.

  1992cited by this paper
• The Use of Technetium-99m-HM-PAO in the Assessment of Patients with Dementia and other Neuropsychiatric Conditions

  1988cited by this paper
• Positron emission tomography with [18F]fluorodeoxyglucose differentiates normal pressure hydrocephalus from Alzheimer-type dementia.

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Characterization of the glymphatic system and early-phase β-amyloid imaging in Alzheimer's disease: a simultaneous PET/MR study.

  2025influential citation
• Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers

  2025cites this paper
• Correlation and Interchangeability of Amyloid, Tau, and Glucose Metabolism PET in Mild Cognitive Impairment and Alzheimer: A Review

  2025cites this paper
• Cerebral amyloid-β, glucose metabolism and hippocampal volume in major depression with and without suspected non-Alzheimer pathophysiology (SNAP)

  2025influential citation
• Perspectives of the European Association of Nuclear Medicine (EANM) on early perfusion imaging in the context of amyloid PET imaging protocols

  2025cites this paper
• Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer’s disease preclinical phase evaluated by dual-phase 18F-florbetaben positron emission tomography

  2024cites this paper
• Multiparametric Chemical Exchange Saturation Transfer MRI Detects Metabolic Changes in Mild Cognitive Impairment Cases at 3.0 Tesla

  2024cites this paper
• Atrophy, hypometabolism and implication regarding pathology in late-life major depression with suspected non-alzheimer pathophysiology (SNAP)

  2023cites this paper
• Early phase amyloid PET or "two birds with one Stone".

  2022cites this paper
• Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier

  2022influential citation
• Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology

  2022cites this paper
• Supplemental Online Content

  2021cites this paper
• Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an 18F-AV-45 study.

  2021cites this paper
• Association of quality of life with structural, functional and molecular brain imaging in community-dwelling older adults

  2021cites this paper
• Texture-Based Analysis of 18F-Labeled Amyloid PET Brain Images

  2021cites this paper
• Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease

  2021cites this paper
• Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer’s clinical syndrome

  2021cites this paper
• Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer’s disease

  2021cites this paper
• High Correlation of Static First-Minute-Frame (FMF) PET Imaging after 18F-Labeled Amyloid Tracer Injection with [18F]FDG PET Imaging

  2021cites this paper
• Cerebral blood flow in mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis.

  2021cites this paper
• NDT_A_336126 3195..3203

  2021cites this paper
• Association Between Lack of Insight and Prefrontal Serotonin Transporter Availability in Antipsychotic-Free Patients with Schizophrenia: A High-Resolution PET Study with [11C]DASB

  2021cites this paper
• Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism

  2020cites this paper
• Classification of Alzheimer’s Disease from 18F-FDG and 11C-PiB PET Imaging Biomarkers Using Support Vector Machine

  2020cites this paper
• Pharmacokinetic modelling for the simultaneous assessment of perfusion and 18F-flutemetamol uptake in cerebral amyloid angiopathy using a reduced PET-MR acquisition time: Proof of concept

  2020influential citation
• Dual-Phase 18F-FP-CIT PET in Corticobasal Syndrome.

  2019cites this paper
• 18F‐FDG PET, the early phases and the delivery rate of 18F‐AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against 15O‐H2O PET

  2019cites this paper
• Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context.

  2019cites this paper
• Quantitative Analysis of Brain 18F-fluordesoxyglucose and Early-Phase 18F-florbetapir Positron Emission Tomography

  2019cites this paper
• Dynamics of proteinopathies in Alzheimer’s disease as measured by PET and CSF biomarkers

  2018cites this paper
• Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder

  2018cites this paper
• Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies

  2018cites this paper
• Can 11C-PiB-PET Relative Delivery R1 or 11C-PiB-PET Perfusion Replace 18F-FDG-PET in the Assessment of Brain Neurodegeneration?

  2018cites this paper
• Visualization of ischemic stroke-related changes on 18F-THK-5351 positron emission tomography

  2018cites this paper
• Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study

  2018cites this paper
• Focused Ultrasound-Induced Blood-Brain Barrier Opening Enhances GSK-3 Inhibitor Delivery for Amyloid-Beta Plaque Reduction

  2018cites this paper
• Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation

  2018cites this paper
• 18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease.

  2018influential citation
• Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer’s Disease

  2018influential citation
• Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease

  2018cites this paper
• An easy way to increase confidence in beta-amyloid PET evaluation.

  2017cites this paper
• Brain amyloid PET interpretation approaches: from visual assessment in the clinic to quantitative pharmacokinetic modeling

  2017cites this paper
• Biodistribution and Radiation Dosimetry for the Tau Tracer 18F-THK-5351 in Healthy Human Subjects

  2017cites this paper
• Early-phase 18F-AV-45 PET Imaging can Detect Crossed Cerebellar Diaschisis Following Carotid Artery Stenosis and Cerebral Hypoperfusion.

  2017cites this paper
• Potential biomarkers and novel pharmacological targets in protein aggregation‐related neurodegenerative diseases

  2017cites this paper
• The Added Value of Dynamic 18F-Florbetapir PET in the Assessment of Dementia With Lewy Bodies.

  2017cites this paper
• Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET

  2017cites this paper
• Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

  2016cites this paper
• Dual-phase amyloid PET: hitting two birds with one stone

  2016cites this paper
• Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

  2016cites this paper